EcoDrugPlus

C-Reactive Protein-Like

Ensembl ID : ENSORLG00000028543
Gene Symbol: LOC111946276
3 Cross references
402 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSORLG00000019555
Gene Symbol: CFTR
4 Cross references
214 Possible Orthologues:

D(1) Dopamine Receptor

Ensembl ID : ENSORLG00000007303
Gene Symbol: LOC101169046
3 Cross references
189 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSORLG00000005582
Gene Symbol: DNMT1
4 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSORLG00000009314
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSORLG00000004407
Gene Symbol: TOP2A
4 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSORLG00000008628
Gene Symbol: TOP2B
4 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSORLG00000013917
Gene Symbol: TOP1A
4 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSORLG00000003456
Gene Symbol: EML4
4 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSORLG00000015835
Gene Symbol: EPHA3
4 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSORLG00000030468
Gene Symbol: F2RL3
4 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSORLG00000015083
Gene Symbol: FAUA
4 Cross references
300 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).